Aibar Aginbay

Aibar Aginbay

Auto-generated profile, based on publicly available information

Aibar Aginbay

Department of Gastroenterology, National Research Oncology Center, Astana, Kazakhstan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2022 in Case Reports in Gastroenterology
Verified
Journal Article
Open access
PDF file
AAAibar Aginbay
Aibar Aginbay
SKSaule Khamzina
Saule Khamzina
MZMarzhan Zhanasbayeva
Marzhan Zhanasbayeva
KKKulpash Kaliaskarova
Kulpash Kaliaskarova
KBKanat Batyrbekov
Kanat Batyrbekov
GKGulnara Kulkayeva
Gulnara Kulkayeva
Oral manifestations of IBD can be specific or nonspecific, due to intestinal malabsorption or induced by pharmacological treatments. Oral manifestations may precede the diagnosis of IBD or interfere with timely diagnosis and treatment. The paradigm of treatment for oral lesions in patients with IBD is based on treating and controlling the intestinal manifestations of the underlying disease as well as local methods of treatment can be used. Here, we report a case of a patient with the oral manifestation of IBD, who responded to treatment with infliximab. The patient was admitted with complaints of long-term nonhealing ulcers of the lips and oral cavity, odynophagia, and there were no intestinal manifestations at that time. The appearance of the disease in 2008 with lesions of the oral cavity, however, Crohn’s disease was diagnosed in 2016. The patient began therapy with azathioprine and prednisolone, and later developed hormone dependence and osteoporosis. In 2020, against the background of immunosuppressive therapy, the patient has an exacerbation, especially increased symptoms from the lesion of the oral cavity. In 2020 was started therapy with vedolizumab, with slight improvement. Due to the ineffectiveness of the latter’s therapy, therapy with monoclonal antibodies (infliximab) was started in February 2021. Currently, patient is in clinical, laboratory, and endoscopic remission.

27 October 2023 in Journal of Clinical Medicine of Kazakhstan
Verified
Journal Article
Open access
PDF file
AAAibar Aginbay
Aibar Aginbay
SKSaule Khamzina
Saule Khamzina
RZRuslan Zhambulayev
Ruslan Zhambulayev
NBNatalya Baromyko
Natalya Baromyko
SSSanzhar Shalekenov
Sanzhar Shalekenov
Syphilitic hepatitis is a rare clinical presentation of syphilis and is easily misdiagnosed. However, clinical and histopathologic manifestations of Syphilitic Hepatitis can imitate other infectious and non-infectious diseases, and the diagnosis should be considered in patients with abnormal liver function tests. We present an unusual case of syphilitic hepatitis presenting with jaundice and abdominal bloating after treatment with benzylpenicillin, liver enzymes, and mucocutaneous findings improved.

1 January 2023 in Diagnostic and Interventional Endoscopy
Verified
Journal Article
Closed access
KBKanat Batyrbekov
Kanat Batyrbekov
ITIrina Ten
Irina Ten
KKKulpash Kaliaskarova
Kulpash Kaliaskarova
AGAinur Galiakbarova
Ainur Galiakbarova
AUAsset Ualikhanov
Asset Ualikhanov
AAAibar Aginbay
Aibar Aginbay
Objective: The aim of this study is an assessment of the effectiveness of endoscopic and x-ray surgical methods in the treatment and prevention of bleeding from varicose veins in patients with cirrhosis of the liver with portal hypertension syndrome of various etiologies. Methods: We analyzed the effectiveness of endoscopic methods and x-ray surgical methods of varicose veins of the esophagus and stomach in patients with cirrhosis of the liver with portal hypertension syndrome over the past 2021. The duration of the study is 12 months, and the follow-up period is 12 months. Results: Fifty-nine patients (23 men and 36 women aged 18-90 years) who received inpatient treatment were examined. Forty-four patients, which is 74.5% of the total number of patients, received endoscopic treatment in the form of endoscopic ligation of esophageal veins, while no complications were observed in the early and late surgical period. Fifteen patients received different types of x-ray surgical methods. Conclusions: The multidisciplinary approach in determining treatment tactics, determining the order of treatment stages, as well as the correct choice of an effec-tive treatment method reduces the number of complications of surgical interventions and relapses and increases remission and survival in patients. The analysis of endoscopic and x-ray surgical methods of treatment performed in a particular clinic for a certain period of time for reliability requires an increase in the follow-up period to 3 and 5 years; if there are positive results, such an approach to treatment can be practiced in other multidisciplinary hospitals of the republic.

7 January 2026 in Oncology, Nuclear Medicine and Transplantology
Verified
Journal Article
Open access
PDF file
LNLyazzat Bekenkyzy Nur
Lyazzat Bekenkyzy Nur
MMMarzhan Marzhan
Marzhan Marzhan
AAAibar Aginbay
Aibar Aginbay
KKKulpash Kaliaskarova
Kulpash Kaliaskarova
ZSZhanat Spatayev
Zhanat Spatayev
BKBairam Kochiyev
Bairam Kochiyev
Posterior reversible encephalopathy syndrome (PRES) is a neurological condition characterized by seizures, encephalopathy, visual disturbances, and headache, often occurring in the context of hypertension and immunosuppressive therapy after solid organ transplantation. Although classically presenting with vasogenic edema in the parieto-occipital regions, atypical patterns may also occur. Here we report our experience with a case of cyclosporine-related PRES after liver transplant and summarize PRES clinical features through a literature review. The case was a 53-year-old man who received a deceased donor liver transplant. His initial immunosuppressive therapy comprised cyclosporine/mycophenolate mofetil/prednisolone. Five months after transplantation, he was admitted to our center with altered mental status. The patient was diagnosed with PRES based on neurological symptoms and neuroimaging findings and recovered after switching from cyclosporine to everolimus. In addition, the lowering of blood pressure with drugs reported in the literature for use in PRES proved to be effective but challenging, requiring the use of multiple agents and only slowly leading to adequate control of hypertensive peaks. Nonetheless, hypertension management and supportive therapy allowed for a complete neurological recovery of the patient. In conclusion, cyclosporine-associated PRES has a generally favorable prognosis with early diagnosis and prompt treatment, including altering or discontinuing CNIs and controlling blood pressure. CNI-associated PRES should be considered in patients exhibiting acute neurological symptoms after transplantation. Early diagnosis and immediate treatment are critical for a favorable prognosis.